Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation

European Journal of Heart Failure

Volumn 16, Issue 4, 2014, Pages 377-383

  Borné, Yan ^a   Persson, Margaretha ^a,b   Melander, Olle ^a   Gustav Smith, J ^a,c,d   Engström, Gunnar ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Atrial fibrillation; Cohort study; Heart failure; NT proBNP; suPAR

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; UROKINASE RECEPTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK FACTOR; SEX DIFFERENCE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MIDDLE AGED;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK FACTORS;

EID: 84937566722     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.49     Document Type: Article

References (48)

1. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC, Cines DB, Huang M,. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006; 311: 656-659.
2. Thuno M, Macho B, Eugen-Olsen J,. suPAR: the molecular crystal ball. Dis Markers 2009; 27: 157-172.
3. Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J,. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011; 270: 32-40.
4. Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, Jeppesen J, Eugen-Olsen J,. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Prev 2011; 20: 609-618.
5. Sidenius N, Nebuloni M, Sala S, Zerbi P, Price RW, Gisslen M, Hagberg L, Vago L, Lazzarin A, Blasi F, Cinque P,. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J Neuroimmunol 2004; 157: 133-139.
6. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Moller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jorgensen T, Haugaard SB,. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268: 296-308.
7. de Bock CE, Wang Y,. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004; 24: 13-39.
8. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J,. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17: 952-960.
9. Outinen TK, Tervo L, Makela S, Huttunen R, Maenpaa N, Huhtala H, Vaheri A, Mustonen J, Aittoniemi J,. Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute Puumala hantavirus infection. PLoS One 2013; 8: e71335.
10. Sehestedt T, Lyngbaek S, Eugen-Olsen J, Jeppesen J, Andersen O, Hansen TW, Linneberg A, Jorgensen T, Haugaard SB, Olsen MH,. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 2011; 216: 237-243.
11. Persson M, Engstrom G, Bjorkbacka H, Hedblad B,. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study. Atherosclerosis 2012; 220: 502-505.
12. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, Sutton GC,. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999; 20: 421-428.
13. Borne Y, Smith JG, Melander O, Hedblad B, Engstrom G,. Red cell distribution width and risk for first hospitalization due to heart failure: a population-based cohort study. Eur J Heart Fail 2011; 13: 1355-1361.
14. Mann DL,. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-998.
15. Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, Kjekshus J, Simonsen S, Froland SS, Gullestad L,. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998; 97: 1136-1143.
16. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR,. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-842.
17. Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BH, Witteman JC,. C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J 2006; 152: 514-520.
18. Engstrom G, Hedblad B, Tyden P, Lindgarde F,. Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: a population-based cohort study. Atherosclerosis 2009; 202: 617-622.
19. Dernellis J, Panaretou M,. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am J Cardiol 2006; 97: 245-248.
20. Issac TT, Dokainish H, Lakkis NM,. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021-2028.
21. Berglund G, Elmstahl S, Janzon L, Larsson SA,. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993; 233: 45-51.
22. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ, Wang TJ,. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009; 302: 49-57.
23. Ingelsson E, Arnlöv J, Sundström J, Lind L,. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 2005; 7: 787-791.
24. Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg AS,. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol 2001; 30 (Suppl 1): S30-S34.
25. Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O,. Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol 2010; 25: 95-102.
26. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
27. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
28. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J,. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96: 4091-4095.
29. Edsfeldt A, Nitulescu M, Grufman H, Gronberg C, Persson A, Nilsson M, Persson M, Bjorkbacka H, Goncalves I,. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke 2012; 43: 3305-3312.
30. Chavakis T, Willuweit AK, Lupu F, Preissner KT, Kanse SM,. Release of soluble urokinase receptor from vascular cells. Thromb Haemost 2001; 86: 686-693.
31. Sitrin RG, Todd RF 3rd, Mizukami IF, Gross TJ, Shollenberger SB, Gyetko MR,. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood 1994; 84: 1268-1275.
32. Pliyev BK, Menshikov MY,. Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation 2010; 33: 1-9.
33. Engstrom G, Melander O, Hedblad B,. Leukocyte count and incidence of hospitalizations due to heart failure. Circ Heart Fail 2009; 2: 217-222.
34. Levine B, Kalman J, Mayer L, Fillit HM, Packer M,. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-241.
35. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P,. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev 2006; 11: 83-92.
36. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL,. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997; 95: 1247-1252.
37. Prabhu SD,. Cytokine-induced modulation of cardiac function. Circ Res 2004; 95: 1140-1153.
38. Engstrom G, Janzon L, Berglund G, Lind P, Stavenow L, Hedblad B, Lindgarde F,. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 2002; 22: 2054-2058.
39. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G,. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999; 353: 1649-1652.
40. Engstrom G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgarde F,. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 2003; 52: 2097-2101.
41. Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D, Keaney JF Jr, Wang TJ, Vasan RS, Benjamin EJ,. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009; 104: 92-96.
42. Adamsson Eryd S, Smith JG, Melander O, Hedblad B, Engstrom G,. Inflammation-sensitive proteins and risk of atrial fibrillation: a population-based cohort study. Eur J Epidemiol 2011; 26: 449-455.
43. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, Platonov PG, Hedblad B, Engstrom G, Wang TJ, Melander O,. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol 2009; 56: 1712-1719.
44. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, Benjamin EJ,. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373: 739-745.
45. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA,. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 2009; 120: 1768-1774.
46. Krum H,. Abraham WT. Heart failure. Lancet 2009; 373: 941-955.
47. Borne Y, Engstrom G, Essen B, Sundquist J, Hedblad B,. Country of birth and risk of hospitalization due to heart failure: a Swedish population-based cohort study. Eur J Epidemiol 2011; 26: 275-283.
48. Kumler T, Gislason GH, Kirk V, Bay M, Nielsen OW, Kober L, Torp-Pedersen C,. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 2008; 10: 658-660.